Celldex Therapeutics, Inc. CLDX
31.10
(0.38)
(1.21%)
as of 25 Sep
- Market cap
- $2.5B
- P/E
- 0.0×
Follow CLDX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(32.44%) | (40.62%) | (48.94%) | (43.88%) | |
| (30.51%) | (37.63%) | (45.36%) | (40.76%) | ||
ROIC |
(1,057.79%) | (1,828.59%) | (4,051.27%) | 0.00% | |
Return on Tangible Assets |
(39.90%) | (52.91%) | (68.32%) | (44.63%) | |
Average Days of Receivables |
0.00 | 270.40 | 53.81 | 94.64 | |
Free Cash Flow per Share |
(2.74) | (3.22) | (3.40) | (3.11) | |
Free Cash Flow |
(181.67) | (213.66) | (226.25) | (242.10) | |
Capital Expenditures |
(2.19) | (2.71) | (4.09) | (6.54) | |
Piotroski F-Score |
— | 1.00 | 2.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(15.19%) | (20.15%) | (24.48%) | (16.43%) | |
Accounts Receivable Turnover |
0.00 | 2.00 | 2.41 | 5.54 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 9,010.07% | 17,016.73% | 31,432.58% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 1,611.69% | 2,850.45% | 5,318.94% | |
Share Based Compensation of Revenue |
0.00% | 1,331.51% | 2,270.77% | 3,905.41% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.80 | 0.82 | 0.78 | 0.78 | |
Depreciation/Fixed assets |
(1.03) | (0.46) | (0.12) | (0.09) | |
Capex/Depreciation |
0.44 | 1.10 | 4.80 | 7.86 | |
Revenue per Share |
0.00 | 0.04 | 0.02 | 0.01 | |
Operating CF per Share |
(2.70) | (3.18) | (3.34) | (3.03) | |
Capex per Share |
(0.03) | (0.04) | (0.06) | (0.08) | |
Capex to Sales |
0.00 | 1.00 | 2.62 | 7.37 | |
Net Profit Margin |
0.00% | (9,513.13%) | (18,182.44%) | (33,883.77%) |
Columns are period end dates